Cancer Res Treat.  2005 Apr;37(2):133-135.

Carboxypeptidase-G2 Rescue in a Patient with High Dose Methotrexate-induced Nephrotoxicity

Affiliations
  • 1Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea. hsahn@snu.ac.kr
  • 2Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.

Abstract

A 13 year-old girl with osteosarcoma and pulmonary tumor recurrence developed acute renal failure following high dose methotrexate (12 g/m2) therapy, she had previously tolerated high dose methotrexate and her renal and hepatic functions were normal. Briefly, 48 hours after beginning methotrexate infusion her methotrexate concentration and creatinine level were 1338.8microM/L and 5.8 mg/dl, respectively. Grade IV oral mucositis and neutropenia with fever developed at 144 hours after MTX infusion. Hydration and alkalinization were continued and leucovorin rescue was intensified based on the plasma MTX concentrations. Plasma exchange was performed twice and hemodialysis 3 times without problems, but methotraxate and creatinine levels remained high, 91.9 microM/L, and 2.5 mg/dl, respectively. After 3 courses of hemodialysis carboxypeptidase-G2 (CPDG2) was administered at 50 U/kg, intravenously over 5 minutes. After 15 minutes of CPDG2 (Voraxaze(TM)) infusion, her plasma MTX concentration was 0.91microM/L and no rebound elevation or side effects developed. Thirteen days post-MTX infusion her renal function had normalized. We report here our experience of a dramatic methotrexate level reduction caused by CPDG2 administration.

Keyword

High dose methotrexate; Acute renal failure; Leucovorin; Carboxypeptidase-G2

MeSH Terms

Acute Kidney Injury
Adolescent
Creatinine
Female
Fever
Humans
Leucovorin
Methotrexate
Neutropenia
Osteosarcoma
Plasma
Plasma Exchange
Recurrence
Renal Dialysis
Stomatitis
Creatinine
Leucovorin
Methotrexate

Figure

  • Fig. 1 Schematic presentation of serum MTX and creatinine levels with time. Short arrows indicate days of plasma exchange, arrowheads indicate days of hemodialysis and the long arrow indicates the day of CPDG2 administration.


Reference

1. Lankelma J, van der Klein E, Ramaekers F. The role of 7-hydroxymethotrexate during methotrexate anti-cancer therapy. Cancer Lett. 1980; 9:133–142. PMID: 7189691.
Article
2. Bleyer WA. Methotrexate: clinical pharmacology, current status and therapeutic guidelines. Cancer Treat Rev. 1977; 4:87–101. PMID: 329989.
Article
3. Flombaum CD, Meyers PA. High-dose leucovorin as sole therapy for methotrexate toxicity. J Clin Oncol. 1999; 17:1589–1594. PMID: 10334548.
Article
4. Relling MV, Stapleton FB, Ochs J, Jones DP, Meyer W, Wainer IW, et al. Removal of methotrexate, leucovorin, and their metabolites by combined hemodialysis and hemoperfusion. Cancer. 1988; 62:884–888. PMID: 3261621.
Article
5. Kawabata K, Makino H, Nagake Y, Tokioka H, Matsumi M, Morita Y, et al. A case of methotrexate-induced acute renal failure successfully treated with plasma perfusion and sequential hemodialysis. Nephron. 1995; 71:233–234. PMID: 8569964.
6. Minton NP, Atkinson T, Sherwood RF. Molecular cloning of the Pseudomonas carboxypeptidase G2 gene and its expression in Escherichia coli and Pseudomonas putida. J Bacteriol. 1983; 156:1222–1227. PMID: 6358192.
7. Widemann BC, Sung E, Anderson L, Salzer WL, Balis FM, Monitjo KS, et al. Pharmacokinetics and metabolism of the methotrexate metabolite, 2,4-diamino-N10-methylpteroic acid. J Pharmacol Exp Ther. 2000; 294:894–901. PMID: 10945838.
8. Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982; 49:1221–1230. PMID: 6174200.
9. Widemann BC, Balis FM, Kempf-Bielack B, Bielack S, Pratt CB, Ferrari S, et al. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer. 2004; 100:2222–2232. PMID: 15139068.
Article
10. Sohn JH, Rha SY, Jeung HC, Shin HJ, Goo YS, Chung HC, et al. Efficacy of pre- and postoperative chemotherapy in patients with osteosarcoma of the extremities. Cancer Res Treat. 2001; 33:520–526.
Article
11. Kim PS, Ko YH, Jung JE, Kim CW, Cho SG, Kim HK, et al. A case of high dose methotrexate-induced acute renal failure successfully treated with plasma exchange and hemodialysis. Korean J Hematol. 2000; 35:58–61.
12. Greil J, Wyss PA, Ludwig K, Bonakdar S, Scharf J, Beck JD, et al. Continuous plasma resin perfusion for detoxification of methotrexate. Eur J Pediatr. 1997; 156:533–536. PMID: 9243235.
Article
13. Jambou P, Levraut J, Favier C, Ichai C, Milano G, Grimaud D. Removal of methotrexate by continuous venovenous hemodiafiltration. Contrib Nephrol. 1995; 116:48–52. PMID: 8529381.
Article
14. Widemann BC, Balis F, Murphy RF, Sorensen JM, Montello MJ, et al. Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction. J Clin Oncol. 1997; 15:2125–2134. PMID: 9164227.
Article
Full Text Links
  • CRT
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr